Literature DB >> 4229180

In vitro and in vivo studies with trasylol, an anticoagulant and a fibrinolytic inhibitor.

A H Dubber, G P McNicol, D Uttley, A S Douglas.   

Abstract

Mesh：

Substances：

Year:  1968        PMID： 4229180     DOI： 10.1111/j.1365-2141.1968.tb01470.x

Source DB:  PubMed          Journal:  Br J Haematol        ISSN： 0007-1048            Impact factor:   6.998


× No keyword cloud information.
  9 in total

Review 1.  Streptokinase: a review of its clinical pharmacology, mechanism of action and therapeutic uses.

Authors:  R N Brogden; T M Speight; G S Avery
Journal:  Drugs       Date:  1973       Impact factor: 9.546

Review 2.  Anticoagulant and thrombolytic drugs. I. Patho-physiological and pharmacological aspects.

Authors:  D Ogston; A S Douglas
Journal:  Drugs       Date:  1971       Impact factor: 9.546

3.  The effect of oxygen on the fibrinolytic enzyme system in vivo.

Authors:  G M Cunningham; G Boyd; J Windebank; F Moran; G P McNicol
Journal:  J Clin Pathol       Date:  1971-11       Impact factor: 3.411

Review 4.  Is there a place for proteinase inhibition? A review of the literature.

Authors:  G D Lister
Journal:  Postgrad Med J       Date:  1969-08       Impact factor: 2.401

Review 5.  Basis of antifibrinolytic therapy.

Authors:  C R Prentice
Journal:  J Clin Pathol Suppl (R Coll Pathol)       Date:  1980

6.  Continuous localized monitoring of plasmin activity identifies differential and regional effects of the serine protease inhibitor aprotinin: relevance to antifibrinolytic therapy.

Authors:  Daryl L Reust; Jennifer A Dixon; Richard A McKinney; Risha K Patel; William T Rivers; Rupak Mukherjee; Robert E Stroud; Karen Madden; Kevin Groves; Milind Rajopadhye; Scott T Reeves; James H Abernathy; Francis G Spinale
Journal:  J Cardiovasc Pharmacol       Date:  2011-04       Impact factor: 3.105

Review 7.  Perioperative management of drug therapy, clinical considerations.

Authors:  M S Smith; H Muir; R Hall
Journal:  Drugs       Date:  1996-02       Impact factor: 9.546

8.  Aprotinin concentration varies significantly according to cardiopulmonary bypass conditions.

Authors:  T Okamura; N Ishibashi; Y Iwata; D Zurakowski; R A Jonas
Journal:  Perfusion       Date:  2008-11       Impact factor: 1.972

9.  Fibrin-fibrinogen degradation products in sera of normal infants and children.

Authors:  W S Uttley; A G Allan; J D Cash
Journal:  Arch Dis Child       Date:  1969-12       Impact factor: 3.791
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.